Pfizer Issues Voluntary Nationwide Recall For Twelve Lots Of Chantix Tablets Due To N-Nitroso Varenicline Content

T-Reuters2021-07-17

Pfizer Inc:Pfizer Issues A Voluntary Nationwide Recall For Twelve Lots Of Chantix® (Varenicline) Tablets Due To N-Nitroso Varenicline Content.Wholesalers, Distributors With Existing Inventory Of The Lots Should Stop Use & Distribution; Quarantine The Product Immediately.Pfizer-Recalling 2 Lots Of Chantix 0.5Mg, 2 Lots Of Chantix 1 Mg Tablets, 8 Lots Of Chantix Kit Of 0.5Mg/1 Mg Tablets Due To Presence Of Nitrosamine.Believes The Benefit/Risk Profile Of Chantix Remains Positive.To Date, Pfizer Has Not Received Any Reports Of Adverse Events That Have Been Related To This Recall.As Communicated By Fda, There Is No Immediate Risk To Patients Taking Chantix.Further Company Coverage:. ((Reuters.Briefs@Thomsonreuters.Com;)).

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
123